GlassScriptPhysician profile
Jaime C Couture
NPI 1184107138
$1,170.02
in general payments reported to CMS, 2019-2025
23 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.63 · 2022: $591 · 2023: $143 · 2024: $85.70 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $199.98 | 2022 | |
| Glaxosmithkline, LLC. | $182.13 | 2021-2023 | Zejula |
| Novartis Pharmaceuticals Corporation | $140.28 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $88.85 | 2022-2023 | Imbruvica |
| Dexcom, INC. | $58.29 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $56.17 | 2024-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $51.54 | 2025 | |
| Astellas Pharma US INC | $49.67 | 2025 | Veozah |
| Novo Nordisk INC | $45.33 | 2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $44.05 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.12 | 2024-2025 | Jardiance |
| Seagen INC. | $34.53 | 2022 | |
| Epizyme, INC. | $20.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.73 | 2023 | Opdivo |
| Sobi, INC | $19.41 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.10 | 2024 | |
| Eisai INC. | $18.40 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.86 | 2025 | Breztri |
| Aveo Pharmaceuticals, INC. | $15.40 | 2022 | |
| Genzyme Corporation | $14.70 | 2022 | |
| Array Biopharma INC | $12.88 | 2022 | |
| Amgen INC. | $12.09 | 2022 | |
| G1 Therapeutics, INC. | $11.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Couture listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.